Log In
BCIQ
Print this Print this
 

Cirmtuzumab (UC-961)

  Manage Alerts
Collapse Summary General Information
Company Oncternal Therapeutics Inc.
DescriptionHumanized IgG1 mAb against receptor tyrosine kinase-like orphan receptor 1 (ROR1)
Molecular Target Receptor tyrosine kinase-like orphan receptor 1 (ROR1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat relapsed or refractory chronic lymphocytic leukemia (CLL)
Regulatory Designation
PartnerUniversity of California San Diego

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/01/2016

Undisclosed

Undisclosed

Undisclosed

04/12/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today